ABOUT Canalevia -CA1
Canalevia-CA1 is a FDA conditionally approved product to treat chemotherapy-induced diarrhea (CID) in dogs. Currently, treatment for this condition is not adequately addressed by other available medications.
Canalevia-CA1 fills a gap in available treatment options, easing the burden of illness and providing a well-tolerated treatment for CID in dogs.
Canalevia-CA1 has a novel mechanism of action that normalizes the fluid influx into the intestinal lumen that can improve the quality of life for the dog.
HOW Canalevia-CA1 WORKS
Canalevia-CA1 treats CID by modulating the hypersecretion of Cl in diarrhea and normalizes fluid influx into the intestinal lumen. Secretory diarrhea (intestinal fluid secretion) is driven by active transepithelial Cl secretion, which creates the electrochemical force for paracellular Na+ secretion and the osmotic driving force for transcellular fluid secretion.
CROFELEMER IS THE ACTIVE INGREDIENT IN CANALEVIA-CA1
Crofelemer in Canalevia-CA1 normalizes the hypersecretion of both the cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride (Cl ) channel and the calcium-activated Cl channel (CaCC) at the luminal membrane of intestinal enterocytes. Disregulation of the CFTR and CaCC channels increases the osmotic gradient and causes excessive fluid influx into the lumen, resulting in secretory diarrhea.
Crofelemer acts within the lumen of the GI tract, targeting channels on the luminal membrane of epithelial cells lining the intestine.
CID is a multifactorial process that leads to luminal electrolyte imbalance including chloride ion hypersecretion by chloride channels. Increased luminal chloride pulls more sodium into the lumen and results in excessive fluid secretion.
Canalevia-CA1 modulates the hypersecretion of chloride ion channels and normalizes fluid influx into the intestinal lumen.
HOW Canalevia-CA1 ACTS LOCALLY IN THE GI TRACT
A healthy GI tract maintains a balance of chloride, sodium, and fluid that allows normal stool consistency.
KEY PRODUCT DIFFERENTIATION
*Metronidazole, loperamide, kaolin/pectin, or sucralfate are NOT FDA approved for use in dogs.
Canalevia-CA1 has not been evaluated in head-to-head studies with metronidazole, loperamide, kaolin/pectin, or sucralfate.
DOSAGE & ADMINISTRATION
60 tablets per bottle
125mg of crofelemer per tablet
Administer one tablet orally twice daily for 3 days for dogs weighing up to 140 pounds. For dogs weighing more than 140 pounds, administer two tablets orally twice daily for 3 days. Tablets should be swallowed whole and should not be broken, crushed or chewed. If the dose is chewed, one additional dose may be administered.
Canalevia-CA1 is a delayed-release tablet product that contains the active ingredient crofelemer, a plant-based botanical product for the treatment of CID in dogs.
Derived from the latex of the Croton lechleri tree, crofelemer is a first-in-class antidiarrheal agent with a unique physiological mechanism of action for chloride ion channel regulation.
Crofelemer modulates the functional imbalance of the chloride channels within the lumen of the GI tract, inhibiting hypersecretion in chloride channels and reinstating normal physiological function.
Canalevia-CA1 acts locally and it is not absorbed into the blood stream, leading to a well tolerated and non-toxic drug product.
WHY Canalevia-CA1 SHOULD BE
YOUR FIRST CHOICE FOR TREATING CID
Approximately 6 million new cancer diagnoses are made in dogs each year. 1
Chemotherapy agents have a high incidence of inducing CID in dogs. Approximately 30% of dogs treated with chemotherapy will experience CID. 2
CID can compromise compliance with the prescribed chemotherapy treatment.
Canalevia-CA1 is the only FDA conditionally approved treatment for CID in dogs.
Canalevia-CA1 normalizes fluid influx in the intestinal lumen to treat chemotherapy-induced diarrhea.
Canalevia-CA1 is only available to veterinarians through select distributors.
1 AVMA. “Cancer in Pets.” AVMA, www.avma.org/resources/pet-owners/petcare/cancer-pets. Accessed 21 Dec. 2021. 2 SOURCE: Jaguar-sponsored survey of US veterinarieans